Trial Profile
Safety and efficacy of brentuximab vedotin in allogeneic transplantation patients with Hodgkin's lymphoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2018
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2018 Results published in the Annals of Hematology
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association